白细胞介素1与惊厥性脑损伤

白细胞介素1（IL－1）是重要的神经免疫介质。研究发现,惊厥后白细胞介素1β（IL－1β）,内源性白细胞介素1受体拮抗剂（IL－1ra)在脑内迅速增加,体内注射IL－1β可加重惊厥及神经元的损伤,而抑制β的作用,则惊厥及神经元损伤明显减轻,本文就近年来的研究进展,简要概括IL－1与惊厥性脑损伤及其神经保护作用的关系,IL－1在惊厥引起的脑损伤过程中的作用机制。     

白介素-1β对壁细胞酸分泌等胃功能的主要作用及机制

白介素（IL）－1β是已知具有胃细胞保护性,抗溃疡,抗分泌和延迟胃排空的最强力因子,它通过刺激胃内前列腺素合成而产生作用。IL－1β通过多种通路抑制培养壁细胞的酸分泌,该抑制发生于后受体水平。IL－1β对分泌酸的壁细胞,和分泌组胺的ECL细胞二者具有阻滞作用。壁细胞表达IL－1受体。IL－1β抑制卡马可和胃泌素刺激的壁细胞酸分泌作用,对组胺刺激也有一定作用。HP感染导致浸润的胃粘膜炎症细胞释放包括IL－1β的细胞因子。IL－1β可通过其对ECL细胞分泌组胺活性的抑制,相应地介导酸分泌的抑制。     

壳寡糖抑制脂多糖诱导的PIECs表达IL-8和VCAM-1作用的初步研究

目的：观察壳寡糖对脂多糖（LPS）诱导的猪髋动脉内皮细胞（PIECs）炎症损伤的影响以及潜在的分子机制。方法：以脂多糖（1g／mE）＊《激PIECs细胞,建立炎症损伤模型,以RT—PCR和Westernblot的方法观察壳寡糖（COS）预保护PIECs细胞24h,对白介素－8（IL－8）和血管细胞粘附分子．1（VCAM－1）表达水平的影响,以及对JNK信号蛋白磷酸化和c-Fos转录因子表达的影响。结果：壳寡糖可抑制脂多糖刺激的PIECs表达IL－8和VCAM－1,并抑制JNK信号通路的磷酸化和转录因子c-Fos的表达。结论：壳寡糖对脂多糖刺激的PIECs细胞中IL－8和VCAM—1表达的抑制作用是通过抑制上游的JNK信号通路磷酸化和转录因子c-Fos的表达实现的,从而缓解脂多糖对细胞造成的炎症损伤。     

白介素-1 β通过JNK/p38信号-转导通路调控肾系膜细胞表达α-平滑肌肌动蛋白

为探讨细胞内丝裂素原活化蛋白激酶（MAPK）家族各亚类信号转导通路在炎症性细胞因子白介素－1β（IL－1β）对大鼠肾系膜细胞（rMC)表型标志物α-平滑肌肌动蛋白（α－SMA）表达及其分布中的调控作用,以IL－1β（10ng/ml)刺激体外培养的rMC,用电穿孔基因转染及免疫杂交法观察IL－1β对α－SMA基因启动子活性及蛋白表达的作用,并用共聚焦荧光显微镜及透射电镜观察IL－1β刺激前后细胞内α-SMA及微丝的分布变化。通过应用PD98059和SB203580特异阻断ERK和p38通路、共转染显性失活JNKK基因特异阻断JNK通路,观察阻断对IL－1β刺激所致α-SMA表达或启动子活性的影响。结果显示,IL－1β刺激6h可明显上调α－SMA启动子活性,在1－2d内显著促进其蛋白合成;IL－1β刺激24h后,细胞内α-SMA及微丝在细胞核周的分布增加。阻断ERK通路对IL－1β诱导的α-SMA表达无明显影响;阻断JNK及p38通路均可使IL－1β诱导的α－SMA表达明显受抑;阻断p38通路的作用比阻断JNK通路更强,而且对基础状态的α-SMA表达也有抑制作用。上述结果提示,IL－1β可刺激rMC发生表型转化,其表型标志物α－SMA可通过基因转录增强而增加蛋白表达,在细胞内的分布向核周转位积聚。JNK及p38通路是介导IL－1β刺激rMC α-SMA表达的主要信号转导途径,而ERK通路不影响IL－1β的这一作用。     

β—受体与炎症

本文主要介绍β－受体结构功能、代谢调节及其与炎症的关系,分析β－受体激动剂、炎症介质及糖皮质激素对β－受体的调节;阐明β－受体激活对炎症过程中血管壁通透性和炎症细胞功能变化的抑制作用及其机制。     

IL—1RAcP的研究进展

IL－1是一重要的炎性细胞因子。它参与介导类风湿关节炎、系统性红斑狼疮等自身免疫性疾病的病理过程。IL－1受体家族有IL－1RI、IL－1RⅡ和IL－1RAcP(IL-1 receptor accessory protein,白细胞介素1受体辅助蛋白）。IL－1RI是功能性受体,IL－1RⅡ是“伪受体”,IL－1RAcP是近年来发现的参与IL－1信号传导的重要分子,它的表达与否的细胞对IL－1的反应相关。醉综述了IL－1RAcP对IL－1与IL－1R结合的影响,IL－1RAcP参与的信号转导及其可能的调节机制。     

白细胞介素13

IL－13是新近发现的一种新的细胞因子,由Th2细胞产生,人IL－13（hIL-13)的分子量为17kd(糖量化）和12．4kD( 非糖基化）;鼠IL－13（mIL-13)的分子量为14kD;二者的氨基酸序列同源性为58％,hIL-13和mIL-13的基因定位于人第5号染色体和鼠第11号染色体上,并与IL－4基因紧密连锁,二者的cDNA同源性为66％,重组IL－13（γIL－13）具有多种生物学活性刺激前髓样细胞增殖,诱导单核细胞表达MHC II类抗原和CD23,促进B细胞增殖,分化和分泌Ig,抑制炎症因子的产生和HIV－1的复制,抗肿瘤等,对其深入研究将有助于认识IL－13在炎症反应的发生和发展以及调节免疫应答方面的作用,并为其临床应用的可能性提供理论依据。     

人白细胞介素—8研究进展

白细胞介素－8（IL－8）是一种在炎症反应中起很重要的作用细胞因子,本就IL－8的基因,蛋白质结构,作用机理及抗炎促炎机理作一简要综述。     

趋化细胞因子及其受体——结构与功能的进展

趋化细胞因子（chemokine）之分子一级结构、cDNA克隆及其基因结构研究确立了其在功能上具选择特异性的α和β亚家族。LPS、IL－1、TNF、IL－4和INF等对其基因的表达起调节作用。α亚家族的代表IL－8基因5’－旁侧区中－94和－71碱基对之间的核苷酸元件为其基因转录激活所必需。IL－8分子N－端的ELR基序为其受体识别所必备。编码IL－8RA和RB、MIP－1αR、MCP－1RA和RB之cDNA已分离获得。G－CSF和LPS可调节IL－8受体基因的表达。     

中药有效成分调控NLRP3 炎症小体活化的研究进展

炎症小体是细胞内组装形成的大分子蛋白复合体,可将白介素-1β(IL-1β) 和IL-18 加工成熟,并诱导细胞焦亡性死亡,在协调对抗病原体感染和生理紊乱的过程中发挥重要作用。Nod 样受体蛋白3(Nod-like receptor protein 3, NLRP3) 炎症小体是迄今为止结构和功能研究得最为明确的炎症小体,其活化后参与免疫性疾病、心血管疾病、神经系统疾病等多种疾病发生及发展过程。研究显示,许多中药有效成分可以调节相关疾病靶细胞中NLRP3 炎症小体的活化。从中药有效成分调节相关疾病靶细胞（如神经细胞、肝肾细胞、内皮细胞、肿瘤细胞等）中NLRP3 炎症小体活化的机制出发,综述近4 年国内外对中药有效成分调节NLRP3 炎症小体活化的研究进展,以期阐释相关中药有效成分的作用特点,并为相关疾病的防治提供一定参考。     

Oxidized low-density lipoprotein induces secretion of interleukin-1β by macrophages via reactive oxygen species-dependent NLRP3 inflammasome activation

Oxidized low-density lipoprotein (ox-LDL) is a critical mediator of atherogenesis. Macrophage uptake of ox-LDL and their subsequent development into foam cells is the principal event in atherosclerosis. Interleukin-1β (IL-1β), a prototypic multifunctional cytokine involved in inflammation, has an important effect on the pathogenesis and progression of atherosclerosis. Here we show that the phagocytosis of ox-LDL can induce human macrophages to secrete IL-1β by activating the NLRP3 inflammasome, and we further show that the activation of the NLRP3 inflammasome is dependent on the generation of reactive oxygen species and is related to the cathepsin B pathway. Furthermore, ox-LDL can upregulate the expression of the pro-IL-1β protein, thus priming IL-1β secretion. Therefore, our results suggest that the role of ox-LDL in atherosclerosis-related inflammation may involve the activation of the NLRP3 inflammasome.     

Reduced expression of NLRP3 and MEFV in human ischemic heart tissue

The innate immune system and, in particular, activation of the multi-protein complex known as the inflammasome complex are involved in ischemic injury in myocardial cells. The nucleotide-binding leucine-rich repeat-containing pyrin receptor 3 (NLRP3) inflammasome has been linked to inflammation and NLRP3 is especially important for increased inflammation in atherosclerosis, which may lead to myocardial infarction. Here we investigated how inflammasome molecules are affected in human ischemic heart tissue. Surprisingly the important member of the inflammasome complex, NLRP3, displayed markedly decreased levels in human ischemic heart tissue compared with non ischemic control heart tissue. However, subsequent gene analysis revealed mutations in NLRP3 in human ischemic heart tissues but not in non-ischemic control tissue. Gene polymorphisms in the NLRP3 inflammasome have been shown to be associated with increased IL-1β and IL-18 production and severe inflammation.The autoinflammatory disorder familial Mediterranean fever (FMF) is associated with decreased expression of the Mediterranean fever gene (MEFV) and increased inflammation. We also observed reduced expression of MEFV in ischemic versus non-ischemic heart tissue. Further analyses showed a mutation in MEFV in human ischemic heart tissue but not in non-ischemic control tissue.Our data show that defects in the inflammasome and associated proteins may be involved in promoting ischemic heart disease.     

Anti-inflammatory Compounds Parthenolide and Bay 11-7082 Are Direct Inhibitors of the Inflammasome

Activation of the inflammasome generates the pro-inflammatory cytokines interleukin-1β and -18, which are important mediators of inflammation. Abnormal activation of the inflammasome leads to many inflammatory diseases, including gout, silicosis, neurodegeneration, and genetically inherited periodic fever syndromes. Therefore, identification of small molecule inhibitors that target the inflammasome is an important step toward developing effective therapeutics for the treatment of inflammation. Here, we show that the herbal NF-κB inhibitory compound parthenolide inhibits the activity of multiple inflammasomes in macrophages by directly inhibiting the protease activity of caspase-1. Additional investigations of other NF-κB inhibitors revealed that the synthetic IκB kinase-β inhibitor Bay 11-7082 and structurally related vinyl sulfone compounds selectively inhibit NLRP3 inflammasome activity in macrophages independent of their inhibitory effect on NF-κB activity. In vitro assays of the effect of parthenolide and Bay 11-7082 on the ATPase activity of NLRP3 demonstrated that both compounds inhibit the ATPase activity of NLRP3, suggesting that the inhibitory effect of these compounds on inflammasome activity could be mediated in part through their effect on the ATPase activity of NLRP3. Our results thus elucidate the molecular mechanism for the therapeutic anti-inflammatory activity of parthenolide and identify vinyl sulfones as a new class of potential therapeutics that target the NLRP3 inflammasome.     

Necroptosis signaling and NLRP3 inflammasome cross-talking in epithelium facilitate Pseudomonas aeruginosa mediated lung injury

Pseudomonas aeruginosa induced acute lung injury is such a serious risk to public health, but the pathological regulation remains unclear. Here, we reported that PA mediated epithelial necroptosis plays an important role in pathological process. Pharmacological and genomic ablation of necroptosis signaling ameliorate PA mediated ALI and pulmonary inflammation. Our results further proved NLRP3 inflammasome to involve in the process. Mechanism investigation revealed the cross-talking between inflammasome activation and necroptosis that MLKL-dependent necroptosis signaling promotes the change of mitochondrial membrane potential for the release of reactive oxygen species (ROS), which is the important trigger for functional inflammasome activation. Furthermore, antioxidants such as Mito-TEMPO was confirmed to significantly restrain inflammasome activation in epithelium, resulting in a reduction in PA induced pulmonary inflammation. Taken together, our findings revealed that necroptosis-triggered NLRP3 inflammasome in epithelium plays a crucial role in PA mediated injury, which could be a potential therapeutic target for pulmonary inflammation.     

Cholesterol Crystals Activate the NLRP3 Inflammasome in Human Macrophages: A Novel Link between Cholesterol Metabolism and Inflammation

Background

Chronic inflammation of the arterial wall is a key element in the pathogenesis of atherosclerosis, yet the factors that trigger and sustain the inflammation remain elusive. Inflammasomes are cytoplasmic caspase-1-activating protein complexes that promote maturation and secretion of the proinflammatory cytokines interleukin(IL)-1β and IL-18. The most intensively studied inflammasome, NLRP3 inflammasome, is activated by diverse substances, including crystalline and particulate materials. As cholesterol crystals are abundant in atherosclerotic lesions, and IL-1β has been linked to atherogenesis, we explored the possibility that cholesterol crystals promote inflammation by activating the inflammasome pathway.

Principal Findings

Here we show that human macrophages avidly phagocytose cholesterol crystals and store the ingested cholesterol as cholesteryl esters. Importantly, cholesterol crystals induced dose-dependent secretion of mature IL-1β from human monocytes and macrophages. The cholesterol crystal-induced secretion of IL-1β was caspase-1-dependent, suggesting the involvement of an inflammasome-mediated pathway. Silencing of the NLRP3 receptor, the crucial component in NLRP3 inflammasome, completely abolished crystal-induced IL-1β secretion, thus identifying NLRP3 inflammasome as the cholesterol crystal-responsive element in macrophages. The crystals were shown to induce leakage of the lysosomal protease cathepsin B into the cytoplasm and inhibition of this enzyme reduced cholesterol crystal-induced IL-1β secretion, suggesting that NLRP3 inflammasome activation occurred via lysosomal destabilization.

Conclusions

The cholesterol crystal-induced inflammasome activation in macrophages may represent an important link between cholesterol metabolism and inflammation in atherosclerotic lesions.     

The role of pannexin1 in the induction and resolution of inflammation

Extracellular ATP is an important signaling molecule throughout the inflammatory cascade, serving as a danger signal that causes activation of the inflammasome, enhancement of immune cell infiltration, and fine-tuning of several signaling cascades including those important for the resolution of inflammation. Recent studies demonstrated that ATP can be released from cells in a controlled manner through pannexin (Panx) channels. Panx1-mediated ATP release is involved in inflammasome activation and neutrophil/macrophage chemotaxis, activation of T cells, and a role for Panx1 in inducing and propagating inflammation has been demonstrated in various organs, including lung and the central and peripheral nervous system. The recognition and clearance of dying cells and debris from focal points of inflammation is critical in the resolution of inflammation, and Panx1-mediated ATP release from dying cells has been shown to recruit phagocytes. Moreover, extracellular ATP can be broken down by ectonucleotidases into ADP, AMP, and adenosine, which is critical in the resolution of inflammation. Together, Panx1, ATP, purinergic receptors, and ectonucleotidases contribute to important feedback loops during the inflammatory response, and thus represent promising candidates for new therapies.     

Acid‐sensing ion channels regulate nucleus pulposus cell inflammation and pyroptosis via the NLRP3 inflammasome in intervertebral disc degeneration

ObjectiveLactate accumulation is an important factor in the intervertebral disc degeneration (IVDD). Currently, the effect and underlying mechanism of action of lactate on nucleus pulposus (NP) cell inflammation during IVDD are unclear. Previous studies have found that the NLRP3 inflammasome plays an important role in the regulation of NP inflammation. This study focused on the regulation of acid‐sensitive ion channels (ASICs) in relation to inflammation and the effect of NLRP3 on pyroptosis levels in NP cells under acidic conditions.DesignFor the in vitro experiments, human NP cells were exposed to 6 mM lactate solution; different groups were either treated with NLRP3 inhibitor or transfected with siRNA against NLRP3, siRNA against ASC or a mix of these, and mRNA and protein expression levels were then assessed. For the in vivo experiment, varying concentrations of lactate were injected into rat intervertebral discs and examined via magnetic resonance imaging (MRI) and histological staining.ResultsExtracellular lactate promoted NLRP3 inflammasome activation and degeneration of the NP extracellular matrix; furthermore, it increased the levels of inflammation and pyroptosis in the NP. Lactate‐induced NLRP3 inflammasome activation was blocked by ASIC inhibitors and NLRP3 siRNA.ConclusionsExtracellular lactate regulates levels of intercellular reactive oxygen species (ROS) through ASIC1 and ASIC3. ROS activate the NF‐κB signalling pathway, thus promoting NLRP3 inflammasome activation and IL‐1β release, both of which promote NP degeneration.     

NLRP3 inflammasome inhibition attenuates silica-induced epithelial to mesenchymal transition (EMT) in human bronchial epithelial cells

Silicosis is an incurable and progressive lung disease characterized by chronic inflammation and fibroblasts accumulation. Studies have indicated a vital role for epithelial-mesenchymal transition (EMT) in fibroblasts accumulation. NLRP3 inflammasome is a critical mediator of inflammation in response to a wide range of stimuli (including silica particles), and plays an important role in many respiratory diseases. However, whether NLRP3 inflammasome regulates silica-induced EMT remains unknown. Our results showed that silica induced EMT in human bronchial epithelial cells (16HBE cells) in a dose- and time-dependent manner. Meanwhile, silica persistently activated NLRP3 inflammasome as indicated by continuously elevated extracellular levels of interleukin-1β (IL-1β) and IL-18. NLRP3 inflammasome inhibition by short hairpin RNA (shRNA)-mediated knockdown of NLRP3, selective inhibitor MCC950, and caspase-1 inhibitor Z-YVAD-FMK attenuated silica-induced EMT. Western blot analysis indicated that TAK1-MAPK-Snail/NF-κB pathway involved NLRP3 inflammasome-mediated EMT. Moreover, pirfenidone, a commercially and clinically available drug approved for treating idiopathic pulmonary fibrosis (IPF), effectively suppressed silica-induced EMT of 16HBE cells in line with NLRP3 inflammasome inhibition. Collectively, our results indicate that NLRP3 inflammasome is a promising target for blocking or retarding EMT-mediated fibrosis in pulmonary silicosis. On basis of this mechanism, pirfenidone might be a potential drug for the treatment of silicosis.     

Zinc depletion regulates the processing and secretion of IL-1β

Sterile inflammation contributes to many common and serious human diseases. The pro-inflammatory cytokine interleukin-1β (IL-1β) drives sterile inflammatory responses and is thus a very attractive therapeutic target. Activation of IL-1β in sterile diseases commonly requires an intracellular multi-protein complex called the NLRP3 (NACHT, LRR, and PYD domains-containing protein 3) inflammasome. A number of disease-associated danger molecules are known to activate the NLRP3 inflammasome. We show here that depletion of zinc from macrophages, a paradigm for zinc deficiency, also activates the NLRP3 inflammasome and induces IL-1β secretion. Our data suggest that zinc depletion damages the integrity of lysosomes and that this event is important for NLRP3 activation. These data provide new mechanistic insight to how zinc deficiency contributes to inflammation and further unravel the mechanisms of NLRP3 inflammasome activation.     

TRPV1 channel mediates NLRP3 inflammasome-dependent neuroinflammation in microglia

Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease in the central nervous system (CNS). The NLRP3 inflammasome is considered an important regulator of immunity and inflammation, both of which play a critical role in MS. However, the underlying mechanism of NLRP3 inflammasome activation is not fully understood. Here we identified that the TRPV1 (transient receptor potential vanilloid type 1) channel in microglia, as a Ca²⁺ influx-regulating channel, played an important role in NLRP3 inflammasome activation. Deletion or pharmacological blockade of TRPV1 inhibited NLRP3 inflammasome activation in microglia in vitro. Further research revealed that TRPV1 channel regulated ATP-induced NLRP3 inflammasome activation through mediating Ca²⁺ influx and phosphorylation of phosphatase PP2A in microglia. In addition, TRPV1 deletion could alleviate mice experimental autoimmune encephalomyelitis (EAE) and reduce neuroinflammation by inhibiting NLRP3 inflammasome activation. These data suggested that the TRPV1 channel in microglia can regulate NLRP3 inflammasome activation and consequently mediate neuroinflammation. Meanwhile, our study indicated that TRPV1–Ca²⁺–PP2A pathway may be a novel regulator of NLRP3 inflammasome activation, pointing to TRPV1 as a potential target for CNS inflammatory diseases.Subject terms: Neuroimmunology, Neuroimmunology